Survivors of allogeneic bone marrow transplants in childhood report no significant long‐term respiratory symptoms: A single‐center analysis over 20 years

2020 ◽  
Author(s):  
Jessica Ball ◽  
Siona Growcott ◽  
Alison Cameron
Keyword(s):  
Bone Marrow ◽  
Respiratory Symptoms ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Bone Marrow Transplants ◽  
Single Center

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.

1997 ◽  
Vol 15 (5) ◽  
pp. 1767-1777 ◽  
Author(s):  
R Szydlo ◽  
J M Goldman ◽  
J P Klein ◽  
R P Gale ◽  
R C Ash ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Treatment Failure ◽  
Allogeneic Bone Marrow ◽  
Myelogenous Leukemia ◽  
Allogeneic Bone ◽  
Bone Marrow Transplants ◽  
Hla Antigen ◽  
Unrelated Donors ◽  
Alternative Donor ◽  
Related Mortality

PURPOSE To compare outcomes of bone marrow transplants for leukemia from HLA-identical siblings, haploidentical HLA-mismatched relatives, and HLA-matched and mismatched unrelated donors. PATIENTS A total of 2,055 recipients of allogeneic bone marrow transplants for chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL) were entered onto the study. Transplants were performed between 1985 and 1991 and reported to the International Bone Marrow Transplant Registry (IBMTR). Donors were HLA-identical siblings (n = 1,224); haploidentical relatives mismatched for one (n = 238) or two (n = 102) HLA-A, -B, or -DR antigens; or unrelated persons who were HLA-matched (n = 383) or mismatched for one HLA-A, -B, or -DR antigen (n = 108). HLA typing was performed using serologic techniques. RESULTS Transplant-related mortality was significantly higher after alternative donor transplants than after HLA-identical sibling transplants. Among patients with early leukemia (CML in chronic phase or acute leukemia in first remission), 3-year transplant-related mortality (+/-SE) was 21% +/- 2% after HLA-identical sibling transplants and greater than 50% after all types of alternative donor transplants studied. Among patients with early leukemia, relative risks of treatment failure (inverse of leukemia-free survival), using HLA-identical sibling transplants as the reference group, were 2.43 (P < .0001) with 1-HLA-antigen-mismatched related donors, 3.79 (P < .0001) with 2-HLA-antigen-mismatched related donors, 2.11 (P < .0001) with HLA-matched unrelated donors, and 3.33 (P < .0001) with 1-HLA-antigen-mismatched unrelated donors. For patients with more advanced leukemia, differences in treatment failure were less striking: 1-HLA-antigen-mismatched relatives, 1.22 (P = not significant [NS]); 2-HLA-antigen-mismatched relatives, 1.81 (P < .0001); HLA-matched unrelated donors, 1.39 (P = .002); and 1-HLA-antigen-mismatched unrelated donors, 1.63 (P = .002). CONCLUSION Although transplants from alternative donors are effective in some patients with leukemia, treatment failure is higher than after HLA-identical sibling transplants. Outcome depends on leukemia state, donor-recipient relationship, and degree of HLA matching. In early leukemia, alternative donor transplants have a more than twofold increased risk of treatment failure compared with HLA-identical sibling transplants. This difference is less in advanced leukemia.

scholarly journals Host origin of the human hematopoietic microenvironment following allogeneic bone marrow transplantation

Blood ◽  
1987 ◽  
Vol 70 (6) ◽  
pp. 1966-1968 ◽  
Author(s):  
J Laver ◽  
SC Jhanwar ◽  
RJ O'Reilly ◽  
H Castro-Malaspina
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Stromal Cells ◽  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Donor Cells ◽  
Host Origin

Abstract The origin of marrow stromal cells post allogeneic bone marrow transplantation (BMT) was studied. Two groups of patients receiving HLA- identical marrow grafts from sex mismatched siblings were included in the study: the first group (eight patients) received conventional marrow grafts and the second group (ten patients) received stromal cell and T cell depleted grafts. All patients showed hematopoietic engraftment with donor cells. Marrow aspirates obtained from these patients were used to establish stromal layers in long-term marrow cultures (LTMC) for 4 to 6 weeks. In both groups, karyotype analysis of nonhematopoietic cultured stromal cells showed host origin even as late as day 760 posttransplantation. Immunofluorescence methods using monoclonal antibodies against components of fibroblasts, macrophages, and endothelial cells, showed that the composition of stromal layers was similar to those obtained from normal controls. Our data indicate that marrow stromal progenitors capable of proliferation are nontransplantable and do not originate from a hematopoietic-stromal common progenitor.

scholarly journals Effect of Cytomegalovirus Infection on 1‐Year Mortality Rates Among Recipients of Allogeneic Bone Marrow Transplants

1998 ◽  
Vol 26 (3) ◽  
pp. 606-610 ◽  
Author(s):  
Atul Humar ◽  
Serena Wood ◽  
Jeff Lipton ◽  
Hans Messner ◽  
Jacinta Meharchand ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cytomegalovirus Infection ◽  
Mortality Rates ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Bone Marrow Transplants
Sign in / Sign up

Export Citation Format

Share Document